Stanford University, Medgenics deal

The university granted Medgenics an exclusive, worldwide license to Stanford’s autologous ex vivo GeneRide promoter-less gene therapy technology. The license is for use in combination with Medgenics’ Transduced Autologous Restorative Gene Therapy (TARGT) technology. Medgenics also received the exclusive right to use the technology to deliver hematopoietic stem cells to treat sickle cell anemia and beta thalassemia. ...